The clinical management of GCTs is complex as they are heterogeneous with regard to disease site and histological subtype(s).1 Furthermore, the limited sensitivity of the current serum and CSF markers AFP and HCG restricts their clinical utility for the management of malignant GCTs.2 AFP is typically raised in the YST subtype and HCG in CHC, but these markers are usually negative in germinoma/seminoma and EC subtypes. Here, AFP is linked to seminoma.